(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

BIOMARCADORES PARA DOENÇA DE PARKINSON

Em AnáliseInvention PatentPCT · US2022075837

Application data

Invention Patent BIOMARCADORES PARA DOENÇA DE PARKINSON de BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA — IPC A61P 25/00
Invention Patent BIOMARCADORES PARA DOENÇA DE PARKINSON de BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA — IPC A61P 25/00. Drawing published by the INPI in the Industrial Property Gazette.

Number

112024003986

Type

Invention Patent

Filing

09/01/2022

Publication

06/04/2024

PCT

US2022075837

Progress at the INPI

  1. Filing09/01/22
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 09/01/2022. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 06/04/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

US

See this company's full portfolio

Inventors

H. G. (pessoa física)

US

J. M. (pessoa física)

US

K. O. (pessoa física)

US

M. M. (pessoa física)

US

R. M. (pessoa física)

US

Technical data

Priority claims

US

63/240,233 · 09/02/2021

US

63/303,102 · 01/26/2022

Abstract

BIOMARCADORES PARA DOENÇA DE PARKINSON.A presente divulgação se refere ao tratamento de doença de Parkinson com fator estimulador de colônia de granulócito-macrófago, bem como métodos de diagnóstico, prognóstico e seleção de paciente.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

06/04/2024

RPI 2787

Alteração de dados cadastrais

#1.1

03/12/2024

RPI 2775

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.